Company intelligence / Profile preview

Carbiotix

Lund (historically/founder university), Skåne, Sweden

Ownership: Private
Development stage: Other

Overview

Carbiotix’s second-generation soluble fiber CarbiAXOS has achieved regulatory approval for cosmetic uses, promising results in a Metformin study, and is being commercially produced for food, feed, and possible future therapeutic uses. The LinkGut platform has been validated in a 300-person study for microbiome diagnostics[1].

Therapeutic areas: Metabolic DisordersGastroenterologyDermatology
Modalities: Microbial therapyLive biotherapeutic product therapyDietary fiber productSmall molecule (related to prebiotic fiber derivatives)
Industry: Molecular Diagnostics

Partnerships

Collaborations with functional food and probiotics companies (individual partners not explicitly named)[1]

Beyond the preview

Go deeper on Carbiotix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carbiotix.

Explore the full profile